SEARCH

SEARCH BY CITATION

Literature Cited

  • 1
    Juliano RL,Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152162.
  • 2
    Thiebaut F,Tsuruo T,Hamada H,Gottesman MM,Pastan I,Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 77357738.
  • 3
    McDevitt CA,Callaghan R. How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 2007; 113: 429441.
  • 4
    Varma MV,Ashokraj Y,Dey CS,Panchagnula R. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol Res 2003; 48: 347359.
  • 5
    Schinkel AH,Smit JJ,van Tellingen O,Beijnen JH,Wagenaar E,van Deemter L,Mol CA,van der Valk MA,Robanus-Maandag EC,te Riele HP, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491502.
  • 6
    Fromm MF. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 12951310.
  • 7
    Benson ABIII,Trump DL,Koeller JM,Egorin MI,Olman EA,Witte RS,Davis TE,Tormey DC. Phase I study of vinblastine and verapamil given by concurrent IV infusion. Cancer Treat Rep 1985; 69: 795799.
  • 8
    Gruber A,Bjorkholm M,Brinch L,Evensen S,Gustavsson B,Hedenus M,Juliusson G,Lofvenberg E,Nesthus I,Simonsson B, et al. A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia. Leuk Res 2003; 27: 323328.
  • 9
    Dinis-Oliveira RJ,Remiao F,Duarte JA,Ferreira R,Sanchez Navarro A,Bastos ML,Carvalho F. P-glycoprotein induction: An antidotal pathway for paraquat-induced lung toxicity. Free Radic Biol Med 2006; 41: 12131224.
  • 10
    Silva R,Carmo H,Dinis-Oliveira R,Cordeiro-da-Silva A,Lima SC,Carvalho F,de Lourdes Bastos M,Remiao F. In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. Arch Toxicol 2010; 85: 315326.
  • 11
    Miller RA. The aging immune system: Primer and prospectus. Science 1996; 273: 7074.
  • 12
    Aggarwal S,Tsuruo T,Gupta S. Altered expression and function of P-glycoprotein (170 kDa), encoded by the MDR 1 gene, in T cell subsets from aging humans. J Clin Immunol 1997; 17: 448454.
  • 13
    Brenner SS,Klotz U. P-glycoprotein function in the elderly. Eur J Clin Pharmacol 2004; 60: 97102.
  • 14
    Machado CG,Calado RT,Garcia AB,Falcao RP. Age-related changes of the multidrug resistance P-glycoprotein function in normal human peripheral blood T lymphocytes. Braz J Med Biol Res 2003; 36: 16531657.
  • 15
    Storch CH,Klimm HD,Heinrich T,Haefeli WE,Weiss J. Plasma LDL cholesterol has no impact on P-glycoprotein (MDR1/ABCB1) activity in human peripheral blood mononuclear cells. Naunyn Schmiedebergs Arch Pharmacol 2007; 376: 135143.
  • 16
    Beck WT,Grogan TM,Willman CL,Cordon-Cardo C,Parham DM,Kuttesch JF,Andreeff M,Bates SE,Berard CW,Boyett JM, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 1996; 56: 30103020.
  • 17
    Mechetner EB,Schott B,Morse BS,Stein WD,Druley T,Davis KA,Tsuruo T,Roninson IB. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Natl Acad Sci USA 1997; 94: 1290812913.
  • 18
    Park SW,Lomri N,Simeoni LA,Fruehauf JP,Mechetner E. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay. Cytometry A 2003; 53: 6778.
  • 19
    Klimecki WT,Taylor CW,Dalton WS. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs. J Clin Immunol 1995; 15: 152158.
  • 20
    Klimecki WT,Futscher BW,Grogan TM,Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 24512458.
  • 21
    Chaudhary PM,Mechetner EB,Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 27352739.
  • 22
    Cianfriglia M,Dupuis ML,Molinari A,Verdoliva A,Costi R,Galluzzo CM,Andreotti M,Cara A,Di Santo R,Palmisano L. HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology 2007; 4: 17.
  • 23
    Taylor BJ,Olson DP,Ivy SP. Detection of P-glycoprotein in cell lines and leukemic blasts: Failure of select monoclonal antibodies to detect clinically significant Pgp levels in primary cells. Leuk Res 2001; 25: 11271135.
  • 24
    Shirasaka Y,Kawasaki M,Sakane T,Omatsu H,Moriya Y,Nakamura T,Sakaeda T,Okumura K,Langguth P,Yamashita S. Induction of human P-glycoprotein in Caco-2 cells: Development of a highly sensitive assay system for P-glycoprotein-mediated drug transport. Drug Metab Pharmacokinet 2006; 21: 414423.
  • 25
    Webb M,Raphael CL,Asbahr H,Erber WN,Meyer BF. The detection of rhodamine 123 efflux at low levels of drug resistance. Br J Haematol 1996; 93: 650655.
  • 26
    Henmi K,Yoshida M,Yoshikawa N,Hirano T. P-glycoprotein functions in peripheral-blood CD4+ cells of patients with systemic lupus erythematosus. Biol Pharm Bull 2008; 31: 873878.
  • 27
    Hitzl M,Drescher S,van der Kuip H,Schaffeler E,Fischer J,Schwab M,Eichelbaum M,Fromm MF. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 293298.
  • 28
    Meaden ER,Hoggard PG,Khoo SH,Back DJ. Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods 2002; 262: 159165.
  • 29
    Perloff MD,von Moltke LL,Fahey JM,Greenblatt DJ. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol 2007; 59: 947953.
  • 30
    Mechetner E. Detection of the MDR1 P-glycoprotein expression and function. Methods Mol Biol 2007; 378: 175193.
  • 31
    Daoud R,Kast C,Gros P,Georges E. Rhodamine 123 binds to multiple sites in the multidrug resistance protein (MRP1). Biochemistry 2000; 39: 1534415352.
  • 32
    De Moerloose B,Dhooge C,Philippe J. Discordance of P-glycoprotein expression and function in acute leukemia. Adv Exp Med Biol 1999; 457: 107118.
  • 33
    Fazlina N,Maha A,Zarina AL,Hamidah A,Zulkifli SZ,Cheong SK,Ainoon O,Jamal R,Hamidah NH. Assessment of P-gp and MRP1 activities using MultiDrugQuant assay kit: A preliminary study of correlation between protein expressions and its functional activities in newly diagnosed acute leukaemia patients. Malays J Pathol 2008; 30: 8793.